ASMMX
Price
$30.00
Change
+$0.37 (+1.25%)
Updated
Jun 2 closing price
Net Assets
3.63B
GFAFX
Price
$87.64
Change
-$0.28 (-0.32%)
Updated
Jun 2 closing price
Net Assets
337.53B
Interact to see
Advertisement

ASMMX vs GFAFX

Header iconASMMX vs GFAFX Comparison
Open Charts ASMMX vs GFAFXBanner chart's image
ASMMX vs GFAFX Comparison Chart in %
View a ticker or compare two or three
VS
ASMMX vs. GFAFX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASMMX is a Hold and GFAFX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
GFAFX has more cash in the bank: 338B vs. ASMMX (3.64B). GFAFX pays higher dividends than ASMMX: GFAFX (0.20) vs ASMMX (0.00). ASMMX was incepted earlier than GFAFX: ASMMX (21 years) vs GFAFX (25 years). ASMMX (0.97) is less costly to investors than GFAFX (0.65). ASMMX is a more actively managed with annual turnover of: 58.00 vs. GFAFX (32.00). GFAFX has a lower initial minimum investment than ASMMX: GFAFX (250) vs ASMMX (1000). GFAFX annual gain was more profitable for investors over the last year : 14.87 vs. ASMMX (5.41). GFAFX return over 5 years is better than : 24.95 vs. ASMMX (-3.89).
ASMMXGFAFXASMMX / GFAFX
Total Expense Ratio0.970.65149%
Annual Report Gross Expense Ratio0.970.65149%
Fund Existence21 years25 years-
Gain YTD7.74510.42574%
Front Load6%N/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets3.64B338B1%
Annual Yield % from dividends0.000.20-
Returns for 1 year5.4114.8736%
Returns for 3 years51.1753.2796%
Returns for 5 years-3.8924.95-16%
Returns for 10 years84.27112.8775%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATEN32.641.10
+3.49%
A10 Networks
UDR36.840.24
+0.66%
UDR
AVD2.60N/A
N/A
American Vanguard Corp
TCBIO20.65-0.13
-0.63%
Texas Capital Bancshares
AUTL1.75-0.09
-4.89%
Autolus Therapeutics plc